Expresión del receptor tipo toll 7 en muestras de tejido con diagnóstico histopatológico de carcinoma escamoso de laringe
Contenido principal del artículo
Resumen
El cáncer es una enfermedad que se caracteriza por alteraciones en las células, que tiene como resultado modificación en los oncogenes, en los genes supresores tumorales y en la estabilidad genética. El cáncer localizado en laringe representa uno de los padecimientos más frecuentes en la patología otorrinolaringológica. Las neoplasias en cabeza y cuello representan 17.6% (108,064) de la totalidad de las neoplasias malignas reportadas al Registro Histopatológico de Neoplasias en México (RHNM) en el año 2007. El 62% son carcinomas cutáneos.
Detalles del artículo
Sección
Cómo citar
Referencias
Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nature Rev Immunology 2008; 8: 59-73.
Stagg J, Johnstone RW, Smyth MJ. From cancer immunosurveillance to cancer immunotherapy.
DGE. Registro Histopatológico de las Neoplasias en México, 2007
Huang B, Zhao J, Unkeless J, Feng ZH, Xiong H. TLR signaling by tumor and immune cells: a double-edged sword. Review. Nature Oncogene 2008; 27: 218-24.
Dunn, GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-98.
Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22: 329-60.
Kiyoshi Takeda, Tsuneyasu Kaisho, Shizuo Akira RD. Toll-Like Receptors, Department of Host Defence, Research Institute for Microbial Diseases, Osaka University, Solution Oriented Research for Science and Technology, Japan Science and Technology Corporation, RIKEN Research Center For Allergy and Inmunology, Annu Rev Immunol 2003; 21: 335-76.
Miyake K. (2007) Semin. Immunol. 19, 3-10
Lee J, Chuang TH, Redecke V, She L, Pitha PM, Carson DA, Raz E.
Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S. Science 2004; 303: 1526-29.
Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Science 2004; 303: 1529-31.
Schon MP, Schon M, Klotz KN. J Invest Dermatol 2006; 126: 1338-47.
Kariko K, Bhuyan P, Capodici J, Weissman D. J Immunol 2004; 172: 6545-49
Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Nat Biotechnol 2005; 23: 457-62.
Sioud M. J Mol Biol 2005; 348: 1079-90.
Marques JT, Williams BR. Nat Biotechnol 2005; 23: 1399-405.
Lan T, Kandimalla ER, Yu D, Bhagat L, Li Y, Wang D, et al. Proc Natl Acad Sci U.S.A. 2007; 104: 13750-55.
Hassan F, Islam S, Tumurkhuug, et al. Intracellular expression of Toll-Like Receptor 4 in neuroblastoma cells and their unresponsiveness to lipopolysaccharide. BMC Cancer 2006; 6: 281-9.
He W, Liu Q, Wuang L, et al. TLR 4 signaling promotes immune escape of human lung cancer cells by inducing immunossuppresive cytokines and apoptosis resistance. Mol Immunol 2007; 44: 2850-9.
Huang B, Zhao J, Shen S, et al. Listeria monocytogenes promotes tumor growth via tumor cell Toll-Like Receptor 2 signaling. Cancer Res
; 67: 4346-52.
Fukata M, Abreu MT. Role of Toll Like receptors in Gastrointestinal Malignancies. Oncogene 2008; 7: 234-43.
Fukata M, Abreu MT. TRL 4 signaling in the intestine in health and disease. Biochem soc trans 2007; 35: 1473-8.
Jego G, Bataille R, Geffroy-Luseau A, et al. Pathogen associated molecular patterns are growth and survival factors of human myeloma cells throught toll-like receptors. Leukemia 2006; 20: 1130-7.
Kelly Mg, Alvero AB, Chen, et al. TLR 4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res
; 66: 3859-68.
Kundu SD, Lee C, Billips Bk, et al. The Toll-Like Receptor pathway a novel mechanism of infection-induced carcinogenesis of prostate epithelial cells. Prostate 2008; 68: 223-9.
Ilvesaro JM, Merrell MA, Swaim TM, et al. Toll-Like Receptor 9 agonists stimulate prostate cancer invacion in vitro. Prostate 2007; 67:
-81.
Jurk M, Vollmer J. Therapeutic applications of synthetic CpG Oligodeoxynucleotides as TLR 9, agonist for immune modulation Bio Drugs 2007; 21: 387-401.
Huang B, Zhao J, Li H, et al. Toll-Like Receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005; 65: 5009-14.
Salaun B, Coste I, Rissoan MC, et al. TRL can directly trigger apoptosis in human cancer cells. J immunol 2006; 176: 4894-901.
Droemann D, Albrecht D, Gerdes J, et al. Human Lung cancer cells express functionally active Toll-Like Receptor 9. Respir Res 2005; 6: 1-10.
Szczepanski M, Stelmachowska M, Striczinski L, et al. Assessment of expression ok Toll.Like receptors 2,3 and 4, in Laryngeal carcinoma. Eur Arch Otorhinolaryngol 2007; 264: 525-53.
Pivarcsi A, Bodai L, Rethi B, et al. Expression and fuction of Toll-Like receptors 2 and 4, in human keratinocytes. Int. Immunol 2003; 15: 721-30.
Schon MP, Shon M. TLR-7 y TLR-8 como blancos para la terapia en el cáncer. Oncogene 2008; 27: 190-9.
Torres A, Storey L, Anders M, et al. Microanálisis de genes aberrantes en la expresión de la queratosis actinica: efecto de las TLR-7 sobre el imiquimod. Br J Dermatol 2007; 157: 1132-47.